Demyelination

WEST PALM BEACH, Fla. — Treatment with clemastine fumarate was linked to accelerated disease and disability progression due to pyroptosis in a small cohort of individuals with multiple sclerosis, according to a presenter at ACTRIMS 2024.

A Boston-area biotech company has received $24 million in Series A funding to develop neurorestorative and remyelinating therapies for a broad range of neurological conditions.

SAN DIEGO — Patients with MS were twice as likely to experience psychiatric morbidity, including depression and anxiety, in the prodromal phase compared with healthy controls, according to research presented at ACTRIMS 2023.